Human Fas Ligand/TNFSF6 enzyme-linked immunoassay kit
| Specification | 96 Test |
|---|---|
| Sensitivity | 0.12 pg/ml (50 μl)；0.84 pg/ml (10 μl)； |
| Standard Curve Range | 1.37~1000 pg/ml |
| Standard Curve Gradient | 7 Points/3 Folds |
| Number of Incubations | 2 |
| Detectable sample | Liquid phase sample of soluble substances. For example: serum, plasma, cell culture supernatant, tissue grinding liquid, etc. |
| Sample Volume | 50 μl/10 μl |
| Type | Fully Ready-to-Use |
| Operation Duration | 120min |
| pg/ml | O.D. | Average | Corrected | |
|---|---|---|---|---|
| 0.00 | 0.0129 | 0.0122 | 0.0126 | |
| 1.37 | 0.0209 | 0.0206 | 0.0208 | 0.0082 |
| 4.12 | 0.0321 | 0.0325 | 0.0323 | 0.0198 |
| 12.35 | 0.0828 | 0.0862 | 0.0845 | 0.0720 |
| 37.04 | 0.2466 | 0.2461 | 0.2464 | 0.2338 |
| 111.11 | 0.7016 | 0.7212 | 0.7114 | 0.6989 |
| 333.33 | 1.8430 | 1.8680 | 1.8555 | 1.8430 |
| 1000.00 | 3.9250 | 4.0234 | 3.9742 | 3.9617 |
Precision
| Intra-assay Precision | Inter-assay Precision | |||||
| Sample Number | S1 | S2 | S3 | S1 | S2 | S3 |
| 22 | 22 | 22 | 6 | 6 | 6 | |
| Average(pg/ml) | 16.9 | 101.4 | 310.4 | 18.1 | 102.9 | 329.4 |
| Standard Deviation | 0.5 | 3.0 | 7.4 | 0.4 | 2.5 | 12.6 |
| Coefficient of Variation(%) | 2.8 | 2.9 | 2.4 | 2.4 | 2.4 | 3.8 |
Intra-assay Precision (Precision within an assay) Three samples of known concentration were tested twenty-two times on one plate to assess intra-assay precision. Inter-assay Precision (Precision between assays) Three samples of known concentration were tested six times on one plate to assess intra-assay precision.
Spike Recovery
The spike recovery was evaluated by spiking 3 levels of human Fas Ligand/TNFSF6 into health human serum sample. The un-spiked serum was used as blank in this experiment.
The recovery ranged from 96% to 127% with an overall mean recovery of 112%.
Sample Values
| Sample Matrix | Sample Evaluated | Range (pg/ml) | Detectable (%) | Mean of Detectable (pg/ml) |
|---|---|---|---|---|
| Serum | 30 | 8.47-38.67 | 100 | 18.25 |
Serum/Plasma – Thirty samples from apparently healthy volunteers were evaluated for the presence of human Fas Ligand/TNFSF6 in this assay. No medical histories were available for the donors. n.d. = non-detectable. Samples measured below the sensitivity are considered to be non-detectable.
Product Data Sheet
Background: Fas Ligand/TNFSF6
Fas Ligand (FasL), also known as CD178, CD95L, or TNFSF6, is a transmembrane protein homotrimer that binds to Fas/CD95 and triggers apoptosis in the Fas-expressing cell. Fas Ligand also binds the soluble decoy receptor DcR3. It is expressed on activated Th1 cells, CD8+ cytotoxic T cells, and NK cells. A soluble form can be released which remains trimeric and retains the ability to bind Fas. Fas Ligand-induced apoptosis plays a central role in the development of immune tolerance and the maintance of immune privileged sites. Tumor cells can evade immune surveillance by upregulating Fas Ligand to kill tumor infiltrating lymphocytes. In gld mice, a Fas Ligand point mutation is the cause of severe lymphoproliferation and systemic autoimmunity.
